Redeye: Nanexa Q2 - Solid progress but a capital injection is on the horizon

Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22. Once the company’s coming financing need is sorted, and the positive progress of NEX-20 and NEX-22 continues, we see the potential for a positive share momentum in the coming 12–18 months. Given the initial pharmacokinetic data from the clinical phase I trial with NEX-20, we nudge our base case to SEK6.4 (6.1).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/